Compare Global X Copper Miners ETF (COPX) vs CVS Health Corp (CVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Copper Miners ETF vs CVS Health Corp — how do they compare? Global X Copper Miners ETF trades at $84.5 (market cap $7.10B), while CVS Health Corp trades at $85.76 (market cap $112.29B). The key difference: CVS Health Corp is far larger — about 15.8× Global X Copper Miners ETF's market cap, and CVS Health Corp pays a 3.03% dividend while Global X Copper Miners ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Global X Copper Miners ETF for 50 Days and CVS Health Corp for 83 Days on average.
| COPX | CVS | |
|---|---|---|
Market Cap | $7.10B | $112.29B |
Volume | 2,871,128 | 7,763,676 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $96.45 | $110.60 |
52-Week Low | $57.43 | $70.08 |
Typical Hold Time | 50 Days | 83 Days |
Enterprise Value | — | $174.64B |
Dividend Yield | — | 3.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
COPX (Global X Copper Miners ETF) trades at $83.58, down 3.13% amid bearish technical signals with 15 sell indicators versus 2 buy signals. The ETF faces pressure despite positive copper market fundamentals, with copper prices reaching all-time highs near $6.85 per pound. Recent news highlights copper's critical role in AI infrastructure and electrification trends, though mining equities have underperformed the underlying metal.
The copper shortage narrative supports long-term growth potential, but near-term headwinds include global surplus projections and Federal Reserve policy concerns. COPX offers leveraged exposure to copper prices, with analysts divided between buying dips and cautious holding patterns given valuation concerns and mining operational challenges.
CVS Health trades at $87.95, up 1.76% on the day, with a bullish technical signal and strong analyst support. Recent earnings beats in Q1 and Q2 2026, alongside steady revenue growth to $402.07B in 2025, highlight operational strength. The stock's valuation appears attractive with a P/E of 23.17 and P/S of 0.27, while a consensus price target of $111.20 suggests significant upside potential. Positive news includes Aetna's 2027 Medicare plan enhancements and a declared quarterly dividend.
The outlook for CVS remains positive, driven by earnings momentum and strategic initiatives in healthcare services. Key risks include reimbursement pressures and regulatory scrutiny, but Wall Street's 85% buy rating and institutional interest underscore confidence. Investors should weigh the stock's growth prospects against margin volatility and debt levels, with the current price offering a favorable entry point relative to targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Global X Copper Miners ETF
COPX tracks the Solactive Global Copper Miners Total Return Index, providing broad exposure to companies worldwide involved in copper mining, refining, and exploration. It serves as an equity-based alternative to copper futures, offering a leveraged play on copper demand driven by global infrastructure and the clean energy transition.
Read more on COPX →About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →
